<DOC>
	<DOCNO>NCT00005042</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth Kaposi 's sarcoma stopping blood flow tumor . PURPOSE : Phase II trial study effectiveness SU5416 treat patient AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>SU5416 Treating Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor effect SU5416 patient chemotherapy refractory cutaneous AIDS-related Kaposi 's sarcoma . II . Determine safety tolerability regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine safety regimen HIV replication immune parameter patient . V. Determine effect regimen overall quality life tumor specific symptom patient . OUTLINE : This multicenter study . Patients receive SU5416 IV twice weekly 4 week . Treatment continue 1 year absence disease progression unacceptable toxicity . Quality life assess . Patients follow 30 day last treatment , every 3 month thereafter . PROJECTED ACCRUAL : A total 29 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , cutaneous AIDSrelated Kaposi 's sarcoma ( KS ) Must fail least 1 standard chemotherapy regimen KS Chemotherapy refractory ( progress anthracyclinebased paclitaxel therapy ) OR Chemotherapy intolerant ( hypersensitivity drug unacceptable toxicity ) HIV positive At least 5 measurable cutaneous lesion No prior radiotherapy intradermal therapy indicator lesion OR KSrelated generalize edema edema extremity without evidence active cutaneous lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 500/mm3 Platelet count least 50,000/mm3 Hepatic : AST great 5.0 time upper limit normal Bilirubin great 2.0 mg/dL ( great 3.0 mg/dL concurrent indinavir therapy ) Renal : No history renal failure Creatinine great 1.8 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within past year No severe unstable angina No history unstable atherosclerotic coronary artery disease require coronary peripheral artery bypass surgery within past 2 year Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity Cremophor Cremophor base drug product No uncontrolled serious infection : Pneumocystis carinii pneumonia Toxoplasmic brain abscess CMV retinitis colitis Cryptococcal meningitis Symptomatic Mycobacterium aviumintracellulare No active malignancy , except : Basal cell skin cancer Carcinoma situ cervix No cerebral bleed No diabetes mellitus clinical evidence severe peripheral vascular disease diabetic ulcer No acute chronic medical psychiatric condition would preclude compliance No history metabolic acidosis nucleoside analogues Anion gap great 11 ( Na Cl , HCO3 ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior immunotherapy AIDSrelated KS recover At least 2 week since prior biologic therapy AIDSrelated KS No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 2 week since prior chemotherapy AIDSrelated KS recover No concurrent systemic chemotherapy Endocrine therapy : At least 2 week since prior hormonal therapy AIDSrelated KS No concurrent hormonal therapy ( include betaHCG ) Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior surgery No prior stereotactic surgery Other : Stable antiretroviral therapy least 4 week prior least 29 day study Concurrent FDA approve antiretroviral agent expand access antiretroviral agent allow At least 3 week since prior investigational agent No concurrent local topical therapy AIDSrelated KS No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>